The lawsuit contends that throughout the specified period, Zoetis executives provided overly optimistic reports on market share and sales growth for flagship products while failing to disclose critical setbacks. Specifically, the complaint alleges that adoption of the canine pain treatment Librela slowed following FDA safety warnings regarding neurological complications in dogs. Furthermore, the filing claims the company’s Simparica Trio lost market share to lower-priced competitors, while dermatology treatments Apoquel and Cytopoint faced increased pressure from new market entrants. Investors who purchased stock during the class period are not currently represented by counsel unless they retain one, and the ability to share in any future recovery does not require serving as a lead plaintiff. The Rosen Law Firm, which is soliciting participants for the litigation, emphasizes that class certification has not yet been granted.